Company Announcements

hVIVO plc

("hVIVO", the "Company" or the "Group")

Director/PDMR Dealings

hVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has been notified that Cathal Friel, Chairman, sold 21,159,177 ordinary shares in the Company earlier today at 29p each ("the Sale") to satisfy institutional demand post the Company's recent capital markets event.

The shares sold were held through Raglan Road Capital Limited, a company owned and controlled by Cathal Friel and his spouse, and Horizon Medical Technologies Limited, an investment vehicle controlled by Cathal Friel.

Cavendish and Peel Hunt both gave their consent to the Sale.

Cathal Friel and the corporate entities detailed above no longer hold any ordinary shares in the Company.

For further information please contact:

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain. 

Notes to Editors

About hVIVO

hVIVO plc (ticker: HVO) is a fast growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.